HeartFlow said today that it won reimbursement coverage from insurer UnitedHealthcare, which will now cover its HeartFlow FFRct fractional flow reserve analysis for its 45 million members.
HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes in flow across coronary lesions.
The Redwood City, Calif.-based company touted that with the new coverage, its HeartFlow FFRct is available to 235 million individuals in the US.
“This decision by UnitedHealthcare underscores the significant value that the HeartFlow Analysis brings to payers, physicians and patients, from both a clinical and economic standpoint. Not only is the HeartFlow Analysis now accessible to tens of millions of additional people, but this advancement also positions HeartFlow as an integral part of the standard approach to heart disease diagnosis and treatment,” prez & CEO Dr. John Stevens said in a press release.
The company said that UnitedHealthcare also adopted a policy which allows for the use of coronary CTA as a first-line test for symptomatic individuals, and that its FFRct analysis is approved to further assess coronary disease seen on a coronary CTA.
In March, HeartFlow said it inked a collaborative research agreement deal with the Imperial College London for research in the areas of medical imaging and deep learning using the company’s FFRct technology.
